Burns Life Sciences Consulting GmbH

AI-Bio research, strategy, product development, and scientific communication.

We help biotech, bioinformatics, AI, and biosecurity organizations understand, evaluate, build, and communicate work at the frontier of AI and biology.

Burns LSC works with teams facing ambiguous AI-Bio questions: what is real, what is useful, what is risky, what should be built next, and how should it be explained to the people who need to act on it?

See how we work

01 — The AI-Bio frontier

AI is making routine bioinformatics easier to automate. The more valuable questions sit upstream.

Which AI capabilities actually work in biological contexts?
Which workflows can be automated, augmented, or turned into products?
Which demos are real, and which are brittle or misleading?
Where do frontier AI systems create new biological risks?
What should an organization build, buy, evaluate, or avoid?
How should complex AI-Bio work be communicated to users, funders, customers, or leadership?

These questions require biological judgment, computational depth, product sense, clear communication, and disciplined execution. That is where we work.

02 — What we do

We help organizations make better decisions and build useful systems at the intersection of AI and biology.

Computational biology Single-cell & spatial omics High-dimensional cytometry AI-assisted scientific workflows LLM & agent evaluation Bioinformatics product strategy AI-biosecurity research Prototype & product development Science communication Project operations

The goal is not to “add AI.” The goal is to find where AI creates real leverage, where it is likely to fail, what should be built, and how the work should be translated into action.

03 — Who we help

Three audiences. One shared problem: ambiguity at the AI-Bio frontier.

Bioinformatics & biotech companies

We help companies integrate AI into products, platforms, workflows, and strategy.

Common projects

AI product strategy
Roadmap review
Workflow automation
AI-native scientific UX
Agentic analysis prototypes
LLM evaluation on biological tasks
Internal tools for analysis, support, or customer success
Customer-facing scientific communication

Typical questions

How should we integrate AI into our product?
Which parts of our workflow are now automatable?
What should our AI roadmap look like?
How do we avoid building a flashy demo that fails in real scientific use?
How do we explain complex AI-Bio capabilities clearly to customers, investors, or internal teams?

AI-biosecurity organizations

We help nonprofits, funders, and research groups study the implications of frontier AI systems for biological risk.

Common projects

Red-line research
AI-bio threat modeling
Dual-use workflow evaluation
Capability assessment
Defensive tooling
Technical research support
Research communication and reporting

Typical questions

What biological capabilities might frontier AI systems enable?
Where are the practical red lines?
How should risky workflows be evaluated?
What tools would help analysts, researchers, or institutions respond effectively?
How can technical research be turned into clear outputs for funders, policymakers, or partner organizations?

Leaders, investors & funders

We help founders, executives, technical leads, investors, and funders understand what is happening at the AI-Bio frontier and what to do next.

Common projects

Strategic briefings
Technical due diligence
Build / buy / partner decisions
Product feasibility assessment
Independent review of AI-Bio claims
Communication strategy for technical or scientific work

Typical questions

Which AI-Bio claims in our pipeline or portfolio are real?
What is actually working at the AI-Bio frontier today?
Should we build, buy, partner, or wait on this capability?
How large is the opportunity, and what could go wrong?
How do we explain this work clearly to our board, LPs, or stakeholders?

04 — Ways to work together

Five engagement shapes, sized to the question.

AI-Bio strategy

A focused engagement to clarify where AI can create value, where it is likely to fail, and what your team should do next.

Typical outputs

Opportunity map
Risk and feasibility assessment
Product or research roadmap
Recommended experiments
Build / buy / partner recommendations
Decision memo for leadership, investors, or funders

AI-Bio prototyping

A hands-on engagement to turn an idea into a working prototype, internal tool, evaluation, or demo.

Typical outputs

Working prototype
Agentic workflow
AI-assisted analysis system
Evaluation harness
Demo-ready product concept
Technical writeup and next-step roadmap

AI-biosecurity research & product development

Technical research and product development for organizations studying biological risk from frontier AI systems.

Typical outputs

Red-line analysis
Model capability assessment
Trend identification and tracking
Research and trend dashboards
Technical report for internal or external audiences

Scientific communication & operations

Support for teams that need complex AI-Bio work turned into clear, organized, communication-ready outputs.

Typical outputs

Reports and white papers
Website or product copy
Grant, funder, or stakeholder materials
Complex project planning, timelines, and execution
Convening, conference, and event planning
Technical-to-nontechnical translation
Operational support for research or product projects

Fractional AI-Bio product or research support

Ongoing support for organizations that need senior judgment across AI, biology, product, communication, and execution — without hiring a full-time team.

This can include product strategy, technical review, prototype supervision, partner evaluation, customer discovery, scientific workflow design, communication support, and project operations.

05 — Why Burns LSC

Burns LSC is led by Tyler and Marie Burns.

Tyler Burns

Deep expertise in computational biology, single-cell and spatial biology, cytometry, AI-assisted scientific workflows, product development, and AI-biosecurity research.

LinkedIn →

Marie Burns

Expertise in science communication and operations — turning complex technical work into clear narratives, usable deliverables, and well-run projects.

LinkedIn →

Together, we help organizations move from ambiguous AI-Bio questions to concrete decisions, prototypes, workflows, and communication-ready outputs.

06 — What people are saying

Selected words from the people we've worked with.

BLS Consulting has brought tremendous value to Alkahest's research efforts. Their extensive expertise helped us advance cutting-edge projects both in the scientific foundation, as well as the technical implementation. They're the rare organization that can distill the ambiguity of advanced research down to pragmatic solutions with demonstrable value.

Scott Lohr Senior Director of Informatics & Engineering, Alkahest Inc.

Tyler's expertise in data science, deep biological knowledge, and mastery of cutting-edge technologies have been instrumental in advancing several of our projects. His innovative thinking, coupled with his organization and responsiveness, make him an invaluable consultant. Tyler is our go-to person whenever we encounter challenges, and I greatly appreciate his commitment to efficiency and passion for both the team and the science.

Bahareh Ajami Assistant Professor of Immunology, Oregon Health & Science University

Tyler's sharp data science expertise on top of his deep biological background and first principles mindset has given us quality solutions every time we've brought him in.

Xiaoyan Qian Senior Computational Biologist, 10x Genomics

Tyler's innovative data analysis solutions transformed our raw data into actionable insights, enabling us to make smarter and more informed decisions going forward. His fast and engaged approach makes working with him very enjoyable and informative, and we look forward to engaging his services again in future projects.

Natalia Becares Principal Scientist, LIfT Biosciences

We greatly appreciated the highly professional collaboration on the analysis and interpretation of single-cell sequencing data to identify regulated genes as potential pharmacodynamic markers within specific cell populations. The team demonstrated strong scientific insight, excellent adaptability, and delivered high-quality results in a timely manner.

Hilmar Ebersbach CSO, ImmunOs Therapeutics

07 — Contact

Let's get down to business.

If you'd like our perspective on an AI-Bio question, or want to explore a potential engagement or partnership, Tyler and Marie maintain active LinkedIn presences — if you're not connected, send a request with a short message. If we can't answer your question directly, we may be able to point you toward someone who can.

Tyler's LinkedIn → Marie's LinkedIn → A compendium of Tyler's social media posts →